AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 17991641 — intervention group
Group type: EXPERIMENTAL
Intervention: High-PUFA (HPUFA) diet providing 36.3% of energy from fat and 9.7% from PUFA
Number of subjects: 24
Study 16786773 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Number of subjects: 0
Study 16786773 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Number of subjects: 0
Study 16786773 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative brachytherapy
Number of subjects: 0
Study 12230933 — intervention group
Group type: EXPERIMENTAL
Intervention: Caspofungin (50 mg/day)
Number of subjects: 123
Study 10684216 — intervention group
Group type: EXPERIMENTAL
Intervention: Emoxipin (2-week monotherapy)
Number of subjects: 95
Study 10684216 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 95
Study 7539202 — intervention group
Group type: EXPERIMENTAL
Intervention: H&E-stained smears of papillary carcinoma
Number of subjects: 34
Study 7539202 — intervention group
Group type: EXPERIMENTAL
Intervention: MGG-stained smears of papillary carcinoma
Number of subjects: 34
Study 2156341 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural redose of 2% chloroprocaine buffered with sodium bicarbonate in the upright position
Number of subjects: 30
Study 2156341 — intervention group
Group type: COMPARATOR
Intervention: Epidural redose of 2% chloroprocaine buffered with sodium bicarbonate in the supine position
Number of subjects: 30
Study 218154 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 percent vidarabine applied topically six times daily for 7 days
Number of subjects: 76
Study 218154 — intervention group
Group type: COMPARATOR
Intervention: Placebo (identically packaged)
Number of subjects: 76
Study 218154 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 percent vidarabine applied topically
Number of subjects: 76
Study 7037982 — intervention group
Group type: EXPERIMENTAL
Intervention: Three doses of Salmonella typhi strain Ty 21a oral vaccine (1‐8 X 10(9) live Ty 21a bacteria per dose)
Number of subjects: 32388
Study 7037982 — intervention group
Group type: COMPARATOR
Intervention: Placebo (three doses)
Number of subjects: 32388
Study 31816452 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical decompression
Number of subjects: 338
Study 30311771 — intervention group
Group type: EXPERIMENTAL
Intervention: Social exclusion in an online ball-tossing game
Number of subjects: 331
Study 30311771 — intervention group
Group type: EXPERIMENTAL
Intervention: Stronger anthropomorphism
Number of subjects: 331
Study 30311771 — intervention group
Group type: EXPERIMENTAL
Intervention: Greater instrumental and sentimental values
Number of subjects: 331
Study 27061921 — intervention group
Group type: EXPERIMENTAL
Intervention: Carboplatin and Vincristine (CV) for NF1 patients
Number of subjects: 127
Study 27061921 — intervention group
Group type: COMPARATOR
Intervention: Carboplatin and Vincristine (CV) for non-NF1 patients
Number of subjects: 127
Study 22967171 — intervention group
Group type: COMPARATOR
Intervention: Implants placed in maxillary native bone (group A)
Number of subjects: 25
Study 22967171 — intervention group
Group type: EXPERIMENTAL
Intervention: Implants placed in sinus-grafted sites (group B)
Number of subjects: 25
Study 22967171 — intervention group
Group type: EXPERIMENTAL
Intervention: Implants placed in group B1 (simultaneous insertion)
Number of subjects: 25
Study 22967171 — intervention group
Group type: EXPERIMENTAL
Intervention: Implants placed in group B2 (6 months after sinus lift)
Number of subjects: 25
Study 21774840 — intervention group
Group type: EXPERIMENTAL
Intervention: Quercetin-enriched cereal bars (130 mg quercetin equivalents)
Number of subjects: 6
Study 21774840 — intervention group
Group type: COMPARATOR
Intervention: Quercetin powder-filled hard capsules (130 mg quercetin equivalents)
Number of subjects: 6
Study 21774840 — intervention group
Group type: EXPERIMENTAL
Intervention: Quercetin-enriched cereal bars
Number of subjects: 6
Study 21774840 — intervention group
Group type: COMPARATOR
Intervention: Quercetin powder-filled hard capsules
Number of subjects: 6
Study 21774840 — intervention group
Group type: EXPERIMENTAL
Intervention: Quercetin-enriched cereal bars and quercetin powder-filled hard capsules
Number of subjects: 6
Study 19620164 — intervention group
Group type: EXPERIMENTAL
Intervention: Helicobacter pylori eradication treatment
Number of subjects: 6695
Study 19620164 — intervention group
Group type: COMPARATOR
Intervention: No treatment (control)
Number of subjects: 6695
Study 17766567 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT) group, 11-week duration
Number of subjects: 152
Study 17766567 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 152
Study 15188898 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser in situ keratomileusis (LASIK)
Number of subjects: 32
Study 15188898 — intervention group
Group type: COMPARATOR
Intervention: Laser epithelial keratomileusis (LASEK)
Number of subjects: 32
Study 15188898 — intervention group
Group type: COMPARATOR
Intervention: LASIK and LASEK
Number of subjects: 32
Study 11791088 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal estradiol (50 microg/day)
Number of subjects: 40
Study 11791088 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 11791088 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral Glucose Tolerance Test (OGTT)
Number of subjects: 40
Study 10896360 — intervention group
Group type: EXPERIMENTAL
Intervention: Grid laser treatment
Number of subjects: 77
Study 10896360 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 77
Study 8677036 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2 mg/kg vecuronium
Number of subjects: 40
Study 8677036 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.3 mg/kg vecuronium
Number of subjects: 40
Study 2187665 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril (50 mg, single oral dose)
Number of subjects: 22
Study 2187665 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 2187665 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril
Number of subjects: 22
Study 7362132 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium nitrate
Number of subjects: 11
Study 7362132 — intervention group
Group type: COMPARATOR
Intervention: Sodium chloride
Number of subjects: 11
Study 31801154 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced Recovery after Surgery (ERAS)
Number of subjects: 35
Study 31801154 — intervention group
Group type: COMPARATOR
Intervention: Conservative regimen
Number of subjects: 35
Study 30828946 — intervention group
Group type: EXPERIMENTAL
Intervention: ECAP-controlled closed-loop SCS
Number of subjects: 134
Study 30828946 — intervention group
Group type: COMPARATOR
Intervention: Open-loop conventional SCS
Number of subjects: 134
Study 28975304 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral cephalexin 500 mg and metronidazole 500 mg every 8 hours for 48 hours
Number of subjects: 403
Study 28975304 — intervention group
Group type: COMPARATOR
Intervention: Placebo every 8 hours for 48 hours
Number of subjects: 403
Study 25799446 — intervention group
Group type: EXPERIMENTAL
Intervention: AH Plus® sealer with immediate post space preparation
Number of subjects: 76
Study 25799446 — intervention group
Group type: EXPERIMENTAL
Intervention: AH Plus® sealer with delayed post space preparation
Number of subjects: 76
Study 25799446 — intervention group
Group type: EXPERIMENTAL
Intervention: MTA Fillapex® sealer with immediate post space preparation
Number of subjects: 76
Study 25799446 — intervention group
Group type: EXPERIMENTAL
Intervention: MTA Fillapex® sealer with delayed post space preparation
Number of subjects: 76
Study 25799446 — intervention group
Group type: COMPARATOR
Intervention: Positive control groups (no treatment)
Number of subjects: 76
Study 25799446 — intervention group
Group type: COMPARATOR
Intervention: Negative control groups (no treatment)
Number of subjects: 76
Study 22906553 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine at a psychotomimetic dose
Number of subjects: 10
Study 22906553 — intervention group
Group type: COMPARATOR
Intervention: Placebo condition
Number of subjects: 10
Study 21116825 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous progressive exercise
Number of subjects: 34
Study 21116825 — intervention group
Group type: EXPERIMENTAL
Intervention: Strenuous exercise until exhaustion
Number of subjects: 34
Study 21116825 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute bout of exercise at 70% of maximal work capacity for 30 min
Number of subjects: 34
Study 21116825 — intervention group
Group type: COMPARATOR
Intervention: Submaximal workload
Number of subjects: 34
Study 19240251 — intervention group
Group type: EXPERIMENTAL
Intervention: GHRH and GHRP-2 infusion
Number of subjects: 47
Study 19240251 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone (T) restoration after leuprolide
Number of subjects: 47
Study 19240251 — intervention group
Group type: EXPERIMENTAL
Intervention: Fasting pulsatile GH secretion
Number of subjects: 47
Study 19240251 — intervention group
Group type: EXPERIMENTAL
Intervention: GHRH-GHRP synergy
Number of subjects: 47
Study 19240251 — intervention group
Group type: EXPERIMENTAL
Intervention: Estradiol (E(2))
Number of subjects: 47
Study 19240251 — intervention group
Group type: EXPERIMENTAL
Intervention: IGF-I
Number of subjects: 47
Study 17976101 — intervention group
Group type: EXPERIMENTAL
Intervention: ICD therapy delivered to patients presenting with stable ventricular tachycardia (VT)
Number of subjects: 161
Study 17976101 — intervention group
Group type: EXPERIMENTAL
Intervention: ICD therapy delivered to patients with ischemic etiology
Number of subjects: 161
Study 17976101 — intervention group
Group type: EXPERIMENTAL
Intervention: ICD therapy delivered to patients with tiered therapy programmed ICDs
Number of subjects: 161
Study 17976101 — intervention group
Group type: EXPERIMENTAL
Intervention: ICD therapy delivered to patients using beta-blockers
Number of subjects: 161
Study 17976101 — intervention group
Group type: COMPARATOR
Intervention: Time to first appropriate therapy between first and second ICDs
Number of subjects: 161
Study 14679381 — intervention group
Group type: EXPERIMENTAL
Intervention: E+ (sucrose, 100 g/l, 1672 kJ)
Number of subjects: 24
Study 14679381 — intervention group
Group type: EXPERIMENTAL
Intervention: E+ (sucrose)
Number of subjects: 24
Study 14679381 — intervention group
Group type: COMPARATOR
Intervention: E- (intense sweeteners)
Number of subjects: 24
Study 11887021 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily mouthrinse with triclosan-zinc for 8 weeks
Number of subjects: 37
Study 11887021 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2% chlorhexidine spray for 2 weeks
Number of subjects: 37
Study 10438868 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal spray vaccination with 15 micrograms of HA and 2 micrograms of HLT
Number of subjects: 60
Study 10438868 — intervention group
Group type: EXPERIMENTAL
Intervention: Two nasal spray vaccinations with 7.5 micrograms of HA with 1 microgram of HLT
Number of subjects: 60
Study 10438868 — intervention group
Group type: EXPERIMENTAL
Intervention: Single spray vaccination with 15 micrograms of HA and 2 micrograms of HLT
Number of subjects: 60
Study 10438868 — intervention group
Group type: COMPARATOR
Intervention: Parenteral virosomal vaccine with 15 micrograms of HA without additional adjuvant
Number of subjects: 60
Study 8658281 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of pefloxacin (Abaktal) and clindamycin
Number of subjects: 0
Study 8658281 — intervention group
Group type: COMPARATOR
Intervention: Cefoxitin
Number of subjects: 0
Study 2272604 — intervention group
Group type: EXPERIMENTAL
Intervention: Tolazamide (daily oral weight-adjusted)
Number of subjects: 24
Study 2272604 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 7450653 — intervention group
Group type: EXPERIMENTAL
Intervention: Tablet
Number of subjects: 8
Study 7450653 — intervention group
Group type: EXPERIMENTAL
Intervention: Retard tablet (enteric-coated)
Number of subjects: 8
Study 7450653 — intervention group
Group type: EXPERIMENTAL
Intervention: Suppository (Euphyllin)
Number of subjects: 8
Study 7450653 — intervention group
Group type: COMPARATOR
Intervention: Intravenous preparation
Number of subjects: 8
Study 31658037 — intervention group
Group type: EXPERIMENTAL
Intervention: Osteopathic manipulation treatment group (OMTG - n=23)
Number of subjects: 42
Study 31658037 — intervention group
Group type: COMPARATOR
Intervention: Active control group (ACG - n=19)
Number of subjects: 42
Study 29644473 — intervention group
Group type: EXPERIMENTAL
Intervention: ACTIVATE™ computer training for 8 weeks
Number of subjects: 70
Study 26356254 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold-water immersion (CWI)
Number of subjects: 10
Study 26356254 — intervention group
Group type: COMPARATOR
Intervention: Passive recovery (PAS)
Number of subjects: 10
Study 25053388 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg veliparib (new formulation) under fasting conditions
Number of subjects: 36
Study 25053388 — intervention group
Group type: EXPERIMENTAL
Intervention: Four 10 mg current formulation capsules under fasting conditions
Number of subjects: 36
Study 25053388 — intervention group
Group type: EXPERIMENTAL
Intervention: Four 10 mg new formulation under fasting conditions
Number of subjects: 36
Study 25053388 — intervention group
Group type: COMPARATOR
Intervention: High-fat meal effect on veliparib
Number of subjects: 36
Study 22664754 — intervention group
Group type: EXPERIMENTAL
Intervention: Machine-assisted cycling
Number of subjects: 27
Study 22664754 — intervention group
Group type: COMPARATOR
Intervention: Conventional ET
Number of subjects: 27
Study 20421537 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel plus carboplatin (paclitaxel at 175 mg/m² IV over 3 hours plus carboplatin AUC = 6 IV over 30 minutes every 3 weeks)
Number of subjects: 46
Study 20421537 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel plus carboplatin
Number of subjects: 46
Study 18826988 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel (300 or 600 mg for 1 day; 300 + 75 or 150 mg daily for 7 days)
Number of subjects: 116
Study 18826988 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet function tests (light transmission aggregometry, whole-blood aggregometry, PFA-100, VerifyNow P2Y12)
Number of subjects: 116
Study 15766390 — intervention group
Group type: EXPERIMENTAL
Intervention: Adaptive filtering method for 16.7 Hz interference suppression
Number of subjects: 0
Study 12472704 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal midazolam 0.3 mg.kg‐1
Number of subjects: 119
Study 12472704 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral midazolam 0.5 mg.kg(‐1)
Number of subjects: 119
Study 12472704 — intervention group
Group type: EXPERIMENTAL
Intervention: Rectal midazolam 0.5 mg.kg(‐1)
Number of subjects: 119
Study 12472704 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual midazolam 0.3 mg.kg(‐1)
Number of subjects: 119
Study 10860225 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxazosin
Number of subjects: 0
Study 10860225 — intervention group
Group type: COMPARATOR
Intervention: Chlorthalidone
Number of subjects: 0
Study 8690204 — intervention group
Group type: EXPERIMENTAL
Intervention: H. pylori-infected subjects before eradication
Number of subjects: 16
Study 8690204 — intervention group
Group type: EXPERIMENTAL
Intervention: H. pylori-infected subjects after eradication
Number of subjects: 16
Study 8690204 — intervention group
Group type: COMPARATOR
Intervention: H. pylori-negative controls
Number of subjects: 16
Study 1805295 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethanol 1 g/kg body weight
Number of subjects: 8
Study 1805295 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethanol 0.5 g/kg body weight
Number of subjects: 8
Study 1805295 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 6137975 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous nerve stimulation (TNS)
Number of subjects: 44
Study 6137975 — intervention group
Group type: COMPARATOR
Intervention: Sham electrical stimulation (Control)
Number of subjects: 44
Study 29903051 — intervention group
Group type: EXPERIMENTAL
Intervention: Ayahuasca
Number of subjects: 29
Study 29903051 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study 29597006 — intervention group
Group type: EXPERIMENTAL
Intervention: Dyadic participation in a lifestyle intervention
Number of subjects: 460
Study 29597006 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual participation in a lifestyle intervention
Number of subjects: 460
Study 29597006 — intervention group
Group type: COMPARATOR
Intervention: Minimal intervention control group
Number of subjects: 460
Study 27084954 — intervention group
Group type: EXPERIMENTAL
Intervention: Afatinib 40 mg/day
Number of subjects: 483
Study 27084954 — intervention group
Group type: COMPARATOR
Intervention: Methotrexate 40 mg/m2/week
Number of subjects: 483
Study 25243574 — intervention group
Group type: EXPERIMENTAL
Intervention: T4 treatment (N = 64)
Number of subjects: 123
Study 25243574 — intervention group
Group type: EXPERIMENTAL
Intervention: T4 treatment (N = 64) with TSH ≥ 5 mIU/L
Number of subjects: 123
Study 25243574 — intervention group
Group type: EXPERIMENTAL
Intervention: T4 treatment (N = 64) with TSH < 5 mIU/L
Number of subjects: 123
Study 25243574 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment (N = 59)
Number of subjects: 123
Study 22252342 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential Feeding (SF)
Number of subjects: 1320
Study 20728265 — intervention group
Group type: EXPERIMENTAL
Intervention: RRP (Retropubic Radical Prostatectomy)
Number of subjects: 1787
Study 20728265 — intervention group
Group type: COMPARATOR
Intervention: Watchful Waiting (WW)
Number of subjects: 1787
Study 20728265 — intervention group
Group type: COMPARATOR
Intervention: Control (nonoperated patients with PCa)
Number of subjects: 1787
Study 20728265 — intervention group
Group type: EXPERIMENTAL
Intervention: RALP (Robot-Assisted Radical Prostatectomy)
Number of subjects: 1787
Study 20728265 — intervention group
Group type: COMPARATOR
Intervention: Control (matched controls without PCa)
Number of subjects: 1787
Study 17286338 — intervention group
Group type: EXPERIMENTAL
Intervention: Neighborhood-based interventions (including mobilization, community awareness, responsible beverage service, underage-access law enforcement, intoxicated-patron law enforcement)
Number of subjects: 0
Study 16047525 — intervention group
Group type: EXPERIMENTAL
Intervention: S Model (mid-level professionals, usually nurses)
Number of subjects: 10
Study 16047525 — intervention group
Group type: COMPARATOR
Intervention: P Model (medical providers)
Number of subjects: 10
Study 12364554 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 20 mg/day
Number of subjects: 86
Study 12364554 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 40 mg/day
Number of subjects: 86
Study 12364554 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 80 mg/day
Number of subjects: 86
Study 12364554 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 86
Study 10427668 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose aspirin (100 mg/d)
Number of subjects: 43
Study 10427668 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 43
Study 7485222 — intervention group
Group type: EXPERIMENTAL
Intervention: 800 mg ibuprofen three times daily for 1 month
Number of subjects: 29
Study 7485222 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg piroxicam daily for 1 month
Number of subjects: 29
Study 7485222 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg sulindac twice daily for 1 month
Number of subjects: 29
Study 1485584 — intervention group
Group type: EXPERIMENTAL
Intervention: HLBI 3 MU intramuscularly 6 days a week (arm A)
Number of subjects: 31
Study 1485584 — intervention group
Group type: COMPARATOR
Intervention: HLBI 1 MU intramuscularly 6 days a week (arm B)
Number of subjects: 31
Study 4023472 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 0
Study 4023472 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-carotene
Number of subjects: 0
Study 4023472 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment A or B
Number of subjects: 0
Study 4023472 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment C or D
Number of subjects: 0
Study 28745470 — intervention group
Group type: EXPERIMENTAL
Intervention: Taurine supplementation (3 g of taurine with 400 mL low fat chocolate milk)
Number of subjects: 9
Study 28745470 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLA) with 400 mL low fat chocolate milk
Number of subjects: 9
Study 27703983 — intervention group
Group type: EXPERIMENTAL
Intervention: McGRATH MAC
Number of subjects: 39
Study 27703983 — intervention group
Group type: EXPERIMENTAL
Intervention: C-MAC
Number of subjects: 39
Study 27703983 — intervention group
Group type: COMPARATOR
Intervention: Macintosh blade
Number of subjects: 39
Study 26425113 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive educational sessions based on WHO Primary Ear and Hearing Resource, Basic Level.
Number of subjects: 30
Study 26425113 — intervention group
Group type: COMPARATOR
Intervention: Usual monthly group meetings (Control).
Number of subjects: 30
Study 23228858 — intervention group
Group type: EXPERIMENTAL
Intervention: Stepped care intervention
Number of subjects: 250
Study 23228858 — intervention group
Group type: COMPARATOR
Intervention: Usual care control group
Number of subjects: 250
Study 21617573 — intervention group
Group type: EXPERIMENTAL
Intervention: Hepatitis A vaccine (2 doses, 6 to 9 months apart)
Number of subjects: 1241
Study 21617573 — intervention group
Group type: EXPERIMENTAL
Intervention: Hepatitis A vaccine coadministered with MMR and varicella vaccines (2 doses of hepatitis A vaccine, 6 to 9 months apart)
Number of subjects: 1241
Study 21617573 — intervention group
Group type: COMPARATOR
Intervention: MMR and varicella vaccines followed by 2 doses of hepatitis A vaccine (6 weeks later, 6 to 9 months apart)
Number of subjects: 1241
Study 18784962 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Number of subjects: 99
Study 18784962 — intervention group
Group type: COMPARATOR
Intervention: No chemotherapy
Number of subjects: 99
Study 16865082 — intervention group
Group type: EXPERIMENTAL
Intervention: Levobupivacaine 0.5% (group L)
Number of subjects: 60
Study 16865082 — intervention group
Group type: COMPARATOR
Intervention: Racemic bupivacaine 0.5% (group B)
Number of subjects: 60
Study 12699469 — intervention group
Group type: EXPERIMENTAL
Intervention: Selenium supplementation (200 micro g daily)
Number of subjects: 1312